Every year on October 18, healthcare professionals, women's health advocates, and public health agencies observe World Menopause Day. Coordinated globally by the International Menopause Society (IMS) in official collaboration with the World Health Organization (WHO), this observance confronts a universal midlife biological transition that affects more than one billion women worldwide, advocating for dignified clinical care, accessible therapies, and an end to workplace and social taboos.
The Biological Transition: Demystifying the Climacteric Phase
Menopause is defined clinically as the permanent cessation of ovarian follicular activity and menstruation, diagnosed retrospectively following 12 consecutive months of amenorrhea (typically occurring between ages 45 and 55, with a global median of 51 years). The physiological transition encompasses distinct phases:
- Perimenopause: The multi-year hormonal fluctuation preceding menopause, characterized by erratic estradiol peaks, declining progesterone, vasomotor hot flushes, sleep disruption, cognitive "brain fog," and mood volatility.
- Cardiovascular Vulnerability: Estrogen provides robust endogenous vascular protection. Following menopause, women experience a sharp acceleration in cardiovascular risk, arterial stiffness, and altered lipid profiles, making ischemic heart disease the leading cause of mortality in postmenopausal women.
- Bone Mineral Density Loss: Rapid declines in circulating estrogen accelerate osteoclastic bone resorption, triggering postmenopausal osteoporosis where women can lose up to 20 percent of their bone density within five to seven years post-menopause.
Evidence-Based Therapeutics: Menopausal Hormone Therapy (MHT)
For decades, widespread misinterpretation of the 2002 Women's Health Initiative (WHI) study generated unwarranted medical panic regarding Menopausal Hormone Therapy (MHT/HRT). Contemporary international consensus guidelines affirm that for symptomatic women under age 60 or within 10 years of menopause onset without contraindications:
- Symptomatic Relief: MHT represents the most effective clinical therapy for severe vasomotor symptoms and genitourinary syndrome of menopause (GSM).
- Primary Bone Protection: Transdermal estrogens combined with micronized progesterone significantly reduce osteoporotic fragility fractures and improve long-term metabolic health.
Workplace Inclusivity and Social Dignity
Surveys reveal that one in ten menopausal women leave the workforce prematurely due to severe unmanaged symptoms and lack of managerial flexibility. World Menopause Day urges employers to implement supportive workplace policies: temperature-controlled offices, breathable uniforms, flexible remote hours, and destigmatized corporate health dialogues.
The 1984 Inception by the International Menopause Society
The initiative for a designated global day dedicated to menopausal health originated with the International Menopause Society (IMS), founded in Paris in 1978 by pioneering endocrinologists and gynecologists, including Dr. Robert Greenblatt and Dr. Wulf Utian.
In 1984, during the 4th International Congress on the Menopause in Lake Placid, New York, IMS leadership recognized that while maternal and pediatric healthcare received significant multilateral attention, the distinct health vulnerabilities of midlife and older women were systematically ignored by international health ministries.
Formal Partnership with the World Health Organization (1999)
In 1999, the IMS formally established an official working relationship with the World Health Organization (WHO). Together, they designated October 18 as World Menopause Day, designating October as World Menopause Month.
The inaugural joint campaign published the groundbreaking report "Research on the Menopause in the 1990s," establishing international clinical standards for hormone therapy, dietary calcium intake, and cardiovascular screening for midlife women across all continents.
Modern Annual Scientific White Papers
Each year, the IMS publishes an authoritative scientific White Paper in its peer-reviewed medical journal Climacteric, focusing on critical clinical topics such as cardiovascular prevention, bone health, cognition and dementia, and lifestyle interventions, translated into dozens of languages to educate primary care physicians globally.
